Sujal Shah - 11 Dec 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: N/A
Reported as of: 11 Dec 2023
Net transaction value: -$972,845
SEC form: 4
Accepted by SEC: 11 Dec 2023, 19:03:17 UTC
Prior SEC filing: 14 Nov 2023
Next SEC filing: 26 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Paul Quinlan, as attorney-in-fact for Sujal Shah

Key filing fact

Sujal Shah filed Form 4 for CymaBay Therapeutics, Inc. on 11 Dec 2023.

Key facts

This page summarizes Sujal Shah's Form 4 filing for CymaBay Therapeutics, Inc..
7 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 11 Dec 2023, 19:03.

Change

Previous filing in this sequence was filed on 14 Nov 2023.
Current net transaction value: -$972,845.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CBAY transaction

Common Stock

Options Exercise

Transaction value: $319,875
Shares: +63,975
Change %: +37%
Price: $5.00
Shares after: 235,276
Date: 11 Dec 2023
Ownership: Direct

CBAY transaction

Common Stock

Sale

Transaction value: $1,278,649
Shares: -63,975
Change %: -27%
Price: $19.99
Shares after: 171,301
Date: 11 Dec 2023
Ownership: Direct
Footnotes: F1, F2

CBAY transaction

Common Stock

Options Exercise

Transaction value: $4,450
Shares: +890
Change %: +0.52%
Price: $5.00
Shares after: 172,191
Date: 11 Dec 2023
Ownership: Direct

CBAY transaction

Common Stock

Sale

Transaction value: $18,521
Shares: -890
Change %: -0.52%
Price: $20.81
Shares after: 171,301
Date: 11 Dec 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CBAY transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -31,036
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 31,036
Exercise price: $5.00
Footnotes: F3

CBAY transaction Derivative

Stock Appreciation Right

Options Exercise

Transaction value: $0
Shares: -12,973
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,973
Exercise price: $5.00
Footnotes: F4

CBAY transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -20,856
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 11 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,856
Exercise price: $5.00
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 5 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 28, 2023.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.78 to $20.56, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The option vested over a four-year period, with one-third of the shares subject to the option vesting on the grant date of December 23, 2013, and the remaining 2/3 of the shares subject to the option vesting ratably on a monthly basis over the 48 months thereafter.

Footnote F4

The award was granted under the CymaBay 2013 Equity Incentive Plan and can be settled in cash or shares of CymaBay common stock, at the sole discretion of CymaBay. The award vested in full on the two-year anniversary of the grant date.

Footnote F5

The option vested over a four-year period, with one-third of the shares subject to the Option vesting on the grant date of January 6, 2014, and the remaining 2/3 of the shares subject to the Option vesting ratably on a monthly basis over the 48 months.